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Abstract 
Deubiquitinating enzymes play an important role in a plethora of therapeutically relevant 
processes, and are emerging as pioneering drug targets. Herein, we present a novel probe 
Ubiquitin Specific Protease (USP) inhibitor, alongside an alkyne-tagged activity-based probe 
analogue. Activity-based proteome profiling identified 12 USPs, including USP4, USP16, and 
USP33, as inhibitor targets using sub-micromolar probe concentrations. This represents the first 
intact cell activity-based profiling of deubiquitinating enzymes. Further analysis demonstrated 
functional inhibition of USP33 and identified a synergistic relationship in combination with ATR 
inhibition, consistent with USP4 inhibition. 
Protein ubiquitination, the post-translational addition of the 76 amino acid protein ubiquitin (Ub), 
is a widespread protein post-translational modification (PTM) in eukaryotic cells.1 Ub processing 
can result in varied linear and branched oligomeric chains, and regulation of this motif serves to 
modulate both protein half-life through the ubiquitin-proteasome system, and a multitude of 
important signalling pathways, for example during activation of the DNA damage response 
(DDR).2 Deubiquitinating enzymes (DUBs) are responsible for removal of Ub marks, and are 
emerging as pioneering drug targets and potential biomarkers across many therapeutic areas, 
notably cancer.3-5 The discovery and development of novel DUB inhibitors has benefitted from 
Ub-derived activity-based probes (ABPs) such as HA-Ub-VME, an HA (epitope)-tagged Ub 
carrying a C-terminal vinylmethyl ester warhead.6-10 These ABPs form extensive interactions 
with their targets and covalently label the active site DUB cysteine, enabling DUB activity to be 
assayed in isolation or profiled in cell lysates.11, 12 However, Ub protein-based probes are 
membrane-impermeable,13, 14 and there is an unmet need for ABPs that can profile DUB activity 
and target engagement directly in the complexity of an intact cell.  
Here we report, to our knowledge, the first cell-permeable small molecule ABP for the Ubiquitin 
Specific Protease (USP) family of DUBs (2). We demonstrate that this probe class efficiently 
labels a range of USPs in a native cancer cell environment at sub-micromolar concentrations, 
and is an effective tool to profile USP inhibitor target engagement through quantitative chemical 
proteomic competition experiments. In addition to comprehensive identification of targets in 
intact cancer cells, target confirmation and functional assays enabled validation of a novel 
irreversible USP inhibitor (1) that showed synergy with inhibition of ATR, a kinase mediating the 
DDR, consistent with activity against USP4 in osteosarcoma cells. 
Following a high-throughput screening (HTS) campaign to identify DUB inhibitors, we 
synthesised 4-chloroacetylpyrrole derivative 1 (Figure 1A) as a follow-up to an initial HTS hit.  
Compound 1 is a sub-micromolar inhibitor of USP4 and low micromolar inhibitor of its 
phylogenetic relative USP11 (Supplementary Figure 1) in a biochemical IC50 assay.  
Consistently, low micromolar inhibition of USP4 and USP11 is observed in human 
osteosarcoma (U2OS) cells, as determined by HA-Ub-VME ABP labelling following cell lysis 
(Figure 1B). As a putative irreversible inhibitor we hypothesised that 1 offers a scaffold for 
profiling the activity of these USPs in cells, and an alkyne-tagged analogue 2 (Figure 1C) was 
synthesised to investigate the potential of this chemotype as a USP ABP. Formation of a 
covalent adduct was confirmed by electrospray mass spectrometry (MS) analysis of 
recombinant USP11 after incubation with 2 (Supplementary Figure 2). Compound 2 retains 
inhibitory potency towards USP4 and USP11, observed by a fluorescence polarisation 
recombinant DUB activity assay using an Ub-TAMRA substrate, whilst negligible inhibition was 
observed for control compound 3, which lacks the chloromethylketone covalent warhead 
(Supplementary Table 1, Supplementary Figure 3).  
Prior to proteomic profiling experiments, we first determined a suitable probe labelling 
concentration. Compound 2 was incubated at varying concentrations with U2OS cells for 1 hour 
prior to cell lysis, followed by copper catalysed azide–alkyne cycloaddition (CuAAC) ligation of 
probe-protein complexes to our previously reported trifunctional capture reagent azido–
TAMRA–biotin AzTB (Supplementary Figure 4).15 Visualisation by in-gel fluorescence revealed 
that 2 labels a number of targets at sub-micromolar concentrations (Supplementary Figure 5). A 
concentration of 125 nM was selected for follow-up experiments to ensure sufficient labelling 
whilst maximising the range for competitive activity-based proteome profiling (ABPP). Loss of 
labelling in heat-treated lysate confirmed the requirement for native protein folding 
(Supplementary Figure 6).  
Competition studies by in-gel fluorescence demonstrated that 1 caused a dose-dependent 
reduction in labelling intensity for specific protein bands at sub-micromolar concentrations 
(Figure 1D), whilst no competition was observed against 3 (Supplementary Figure 7). Proteome-
wide in-cell target identification was performed using spike-in SILAC methodology,16 as 
previously described.17, 18 U2OS cells were treated for 1 hour with 125 nM of 2 after a 30 minute 
pre-incubation with a fixed concentration of 1 (0 nM, 125 nM, 625 nM, 5 µM, 10 µM) or 5 µM of 
3. Competition lysates were mixed in a 2:1 ratio with 2-treated ‘spike’ prior to CuAAC ligation, 
and 2-labelled proteins were enriched on NeutrAvidin-Agarose resin and trypsin digested.  
Nanoscale liquid chromatography-MS/MS analysis showed that 125 nM 2 labels 12 USPs in 
intact cells (Figure 2A, Supplementary Dataset 1), a selection of which were validated through a 
fluorescence-intensity recombinant DUB activity assay, using an Ub-Rhodamine substrate 
(Table 1). By comparison, although HA-Ub-VME (9,913 Da) labels a broader range of DUBs in 
cell lysate, 1 (314 Da) demonstrates a much higher ligand efficiency than its Ub-based 
counterpart, and uniquely enables intact cell USP profiling. Despite its small size, USP labelling 
by 2 is considerably more specific than widely used cysteine-reactive small molecule probes; for 
example, alkyne-tagged iodoacetamide has been reported to competitively label 3 USPs at 10 
µM in cancer cell lysates, whilst a recently reported caged-BK derivative labels 2 USPs at 200 
µM in HeLa cells.19, 20 Profiling the activity of 2 against an extended panel of recombinant DUBs 
identified additional USP targets (USP2, USP6, USP8, USP13, USP20, and USP30) with 
inherently low expression in U2OS cells21 (Supplementary Table 2). Conversely 2 demonstrated 
low potency when profiled against alternative DUB families, suggesting that this probe has a 
preference for USPs. 
Compound 2 displays a broad detection range in competitive ABPP, with significant competition 
observed from 1- to 80-fold excess 1. Competition with 5 µM of 3 was negligible compared to 
analogous treatment with 1 (Supplementary Figure 8). As predicted, USP4 showed significant 
competition, whilst USP16 and USP33 were unexpectedly identified as the most potent USP 
targets of 1. USP11 was also significantly competed, along with USP3, USP10, USP15, USP19, 
and USP22. USP5 and USP9x, though identified by 2, were not significantly competed across 
this competition range, whilst USP7 showed only limited competition at 10 µM (data not shown). 
Variable expression of the aforementioned USPs has previously been implicated in cancer, 
including roles in p53 signalling,4 metastatic grade,22 and the hypoxic response.23, 24 The 
competitive probe engagement observed by ABPP was validated for a selection of these USPs 
by Western blot (Figure 2B), and newly identified USP targets of 1 were further validated by 
HA-Ub-VME ABP labelling (Figure 2C, Supplementary Figure 9).  
In total, on competition with 625 nM of 1, 27 significantly competed hits were identified 
(Supplementary Table 3, Supplementary Figure 10). These hits revealed significant enrichment 
for oxidation-reduction processes, cell redox homeostasis, and protein deubiquitination 
biological GO terms by STRING network analysis (Figure 2D). As well as the USP targets 
already described, redox process enzymes including 5 thioredoxins, related nucleoredoxin25 and 
2 glutathione transferase domains were competed, as might be expected for this electrophilic 
chemotype. PTGES2, which showed the greatest ratio fold change, contains the consensus 
region and the active site cysteine of the redox enzymes glutaredoxin and thioredoxin.26 A full 
list of the 27 protein targets and associated GO terms is detailed in Supplementary Table 3.  
We next examined functional inhibition of a novel USP target by 1 in U2OS cells. USP33 has 
been reported to deubiquitinate and consequently stabilise CP110, a key regulator of 
centrosome duplication and thus genomic stability.27 U2OS cells were treated with DMSO or 1 
(10 µM) for 24, 48 and 72 hours, and cell lysates analysed by western blot (Figure 3A). 
Compound 1-treatment led to decreased CP110 protein levels, consistent with decreased 
stability following USP33 inhibition.  
USPs which regulate genomic integrity show promise as drug targets in combination with known 
DNA damaging chemotherapeutics and through synthetic lethal approaches.3 For example, 
USP4 promotes homologous recombination (HR) of DNA double strand breaks (DSBs),28, 29 and 
USP16 has also been implicated in DSB repair30: both of which are prominent USP targets of 1 
in U2OS cells by competitive ABPP. ATM and ATR are DNA damage checkpoint kinases that 
regulate the response to DSBs and DNA damage induced replication stress respectively, whose 
inhibition has been investigated as an approach for tumour cell sensitisation.31 For example, 
ATR inhibition has been previously reported to induce synthetic lethality in ATM deficient cells.32-
34 Profiling the antiproliferative effects of 1 in HeLa cells in combination with siRNA knockdown 
of ATR or ATM, revealed a synthetic lethal relationship between 1 and ATR that was not 
observed for ATM (Supplementary Figure 11). To establish a synergistic relationship, 1 was 
tested in combination with well-characterised ATR and ATM inhibitors VE-82133 and KU-5593335 
(Figure 3B) in U2OS cells, and synergism determined by calculating drug combination indexes 
(CI, CompuSyn software). As single agents, 1 demonstrated an IC50 of 1.7 µM after 6 days in 
U2OS cells (measured using a cell proliferation MTS assay), whilst VE-821 and KU-55933 
demonstrated IC50 values of 4.1 and 15.1 µM, respectively (Supplementary Figure 12). In 
combination, 1 demonstrated synergy with VE-821 (CI = 0.60) but not KU-55933 (CI = 1.41) 
(Figure 3C). This synergy is in agreement with previous siRNA studies that have shown 
depletion of USP4 impairs DNA repair, but does not affect the ATR-governed G2/M DNA 
damage checkpoint.36 However, based on the multiple targets of 1 identified by ABPP we 
postulate that several factors are contributing to the observed effect, including the additional 
USP and redox process enzyme targets of 1, the full characterisation of which requires further 
experiments. 
In summary, we report a cell permeable ABP and its quantitative proteomic application to profile 
USP activity and target engagement in osteosarcoma cells that complements Ub-derived ABPs, 
which are limited to in-lysate profiling. 2 displays sub-micromolar labelling affinity towards 12 
USPs, including several with clinical relevance or biomarker potential.37 ABPP demonstrated 
that the parent compound 1 has good potency against USP4, USP16, and USP33 in U2OS 
cells; consistent with this profile, 1 was shown to functionally inhibit USP33, and to synergise 
with ATR kinase inhibition. Potential use of derivatives of 1 are greatly hampered by the lack of 
selectivity of the compounds as well as their very limited plasma stability. Compound 2 
establishes the potential for in-cell USP probes as a tool for target identification, and we 
anticipate that future generations of small molecule ABP will be useful in exploring a wide range 
of DUB biology in cells, as well as for competitive profiling against DUB inhibitors both in vitro 
and in vivo. 
Methods  
Chemical synthesis and experimental procedures are included in the supplementary 
information.  
Associated content 
Supporting Information Available: this material is available free of charge via the Internet.  The 
mass spectrometry proteomics data have been deposited to the ProteomeXchange Consortium 
via the PRIDE38 partner repository with the dataset identifier PXD004875. 
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 Figure 1. Compound 1 inhibits USP4 and USP11 and outcompetes labelling by compound 2 in intact U2OS cells. A) Structure of 1. 
B) Western blot analysis of HA-Ub-VME ABP labelling of indicated DUBs following treatment with 1. Inhibition was observed as a 
loss of (ABP-labelled) upper band intensity. Values represent percentage inhibition. C) Structure of 2. D) In-gel fluorescence 
analysis of 2 (125 nM) labelled U2OS proteome in competition with 1.  
 
 
 
 
Figure 2. Compound 2 competitively labels USPs. A) Quantitative MS analysis of USP targets of 2 (125 nM) competed by 1 at 
indicated concentrations. The dashed line indicates a 1.5 fold change in ratio (log
2 
= 0.58). B) Validation by immunoblotting of 
USP16, USP33, USP4 and USP11 competitive labelling and pulldown by 2 (2.5 µM). UCHL3 is included as a non-USP control. SN: 
supernatant. C) Target validation by immunoblotting HA-Ub-VME ABP labelling of indicated DUBs following treatment with 1. 
Inhibition was observed as a loss of (ABP-labelled) upper band intensity. Values represent percentage inhibition. D) GO annotations 
(biological process) significantly enriched for the 27 targets of 2 (125 nM) competed by 1 (625 nM), obtained from STRING. The 
number of associated proteins is indicated. 
  
Table 1. Biochemical IC
50
s of 2 against recombinant DUB targets identified by quantitative MS analysis. Values were measured 
using an Ub-Rhodamine fluorescent intensity assay. 
 
 
Biochemical  
IC50 (µM)  
Biochemical  
IC50 (µM) 
USP4 0.05 USP15 1.71 
USP11 0.21 USP10 2.72 
USP16 0.14 USP7 44.2 
USP19 0.35 USP5 >100 
 
 Figure 3. Compound 1 functionally inhibits USP33 leading to CP110 instability and synergises with ATR inhibition. A) Western blot 
analysis of 1-treated U2OS cells. B) Structures of ATM inhibitor KU-55933 and ATR inhibitor VE-821. C) Chou-Talalay analysis of 
drug combination treatments. CI: combination index. 
 
